((S)-1-benzylallyl)carbamic acid tert-butyl ester

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ((S)-1-benzylallyl)carbamic acid tert-butyl ester
• 英文别名: tert-butyl (S)-(1-phenylbut-3-en-2-yl)carbamate；(S)-tert-butyl 1-phenylbut-3-en-2-ylcarbamate；(3S)-3-(tert-butoxycarbonylamino)-4-phenyl-1-butene；(S)-2-tert-butoxycarbonylamino-1-phenyl-but-3-ene；tert-butyl N-[(2S)-1-phenylbut-3-en-2-yl]carbamate
• 化学式: C₁₅H₂₁NO₂
• 分子量: 247.337
• InChiKey: WNAHEVXTGAEKIY-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ((S)-1-benzylallyl)carbamic acid tert-butyl ester 在 sodium hydroxide 、 9-borabicyclo[3.3.1]nonane dimer 、 草酰氯 、 双氧水 、 二甲基亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 2.33h， 生成 3-[(tert-butoxycarbonyl)amino]-4-phenylbutanaldehyde
  参考文献：
  名称：

  Amino Diol HIV Protease Inhibitors. 1. Design, Synthesis, and Preliminary SAR

  摘要：

  A series of HIV protease inhibitors containing a novel C-2 symmetrical ''aminodiol'' core structure were prepared from amino acid starting materials. The ability of the aminodiols to inhibit HIV replication in cell culture is comparable to their ability to inhibit the isolated enzyme, a result compatible with good cell membrane penetration by this class of compounds. Optimization of the structure-activity in this series led to aminodiol 9a (K-i = 100 nM; ED(50) (HIV-1) = 80 nM) containing P-1/P-1', benzyl and P-2/P-2' Boc substituents. Compound 9a is a selective inhibitor of HIV protease versus other aspartyl proteases such as human renin, human cathepsin D, and porcine pepsin. In addition, 9a is equipotent against HIV-1 and HIV-2 in cell culture and demonstrates similar activity in infected T-lymphocytes and PBMCs. After iv and oral administration in rats, 9a displayed significant oral bioavailability (ca. 40%) and a promising plasma elimination half-life (4 h).

  DOI：

  10.1021/jm00038a005
• 作为产物：
  描述：

  N-乙酰-L-苯丙氨酸 在 三聚甲醛 、 四氯化碳 、 sodium 、 sodium hydride 、 对甲苯磺酸 、 三苯基膦 作用下， 以 四氢呋喃 、 水 、 异丙醇 为溶剂， 20.0~80.0 ℃ 、101.33 kPa 条件下， 反应 12.0h， 生成 ((S)-1-benzylallyl)carbamic acid tert-butyl ester
  参考文献：
  名称：

  一种安普那韦中间体的制备方法

  摘要：

  本发明涉及一种抗艾滋病药物安普那韦中间体的合成方法，具体涉及一种(2R,3S)-1,2-环氧基-3-(叔丁氧羰基氨基)-4-苯基丁烷的合成方法，包括以下步骤：以L-苯丙氨酸为原料，与乙酸酐反应生成N-乙酰-L-苯丙氨酸，然后经Mannich反应，Appel反应，烯烃环氧化作用得到该中间体，该方法制备(2R,3S)-1,2-环氧基-3-(叔丁氧羰基氨基)-4-苯基丁烷路线合理，操作性强，收率高，易于实现工业化生产。

  公开号：

  CN105348224A

文献信息

• [EN] HIV PROTEASE INHIBITING COMPOUNDS<br/>[FR] COMPOSES INHIBITEURS DE LA PROTEASE DU VIH
  申请人：ABBOTT LAB

  公开号：WO2005061487A1

  公开（公告）日：2005-07-07

  A compound of the formula (I) is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

  公开了一种公式(I)的化合物作为HIV蛋白酶抑制剂。还公开了用于抑制HIV感染的方法和组合物。
• NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF
  申请人：SEATTLE GENETICS, INC.

  公开号：US20150023989A1

  公开（公告）日：2015-01-22

  The present application relates to new antibody drug conjugates (ADCs) of N,N dialkylauristatins directed against the target FGFR2, drug metabolites of said ADCs, a method for producing said ADCs, the use of said ADCs for the treatment and/or prevention of illnesses as well as the use of said ADCs for producing pharmaceuticals for the treatment and/or prevention of illnesses, particularly of hyperproliferative and/or angiogenic diseases such as carcinosis. Such treatments can be carried out as monotherapy or in combination with other pharmaceuticals or additional therapeutic measures.

  本申请涉及针对FGFR2靶点的新抗体药物结合物（ADCs），所述ADCs的药物代谢产物，生产所述ADCs的方法，利用所述ADCs治疗和/或预防疾病以及利用所述ADCs生产用于治疗和/或预防疾病的药物，特别是治疗高增殖和/或血管生成性疾病如癌症。这种治疗可以作为单药疗法进行，也可以与其他药物或额外的治疗措施结合使用。
• NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME
  申请人：SEATTLE GENETICS, INC.

  公开号：US20150246136A1

  公开（公告）日：2015-09-03

  The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.

  本专利申请涉及针对靶向表皮生长因子受体（EGFR，基因ID 1956）的新型结合物-药物共轭物（ADCs）N，N-二烷基月桂酰基蛋白酶抑制剂，这些ADCs的有效代谢物，生产这些ADCs的方法，利用这些ADCs治疗和/或预防疾病，以及利用这些ADCs生产用于治疗和/或预防疾病的药物，特别是治疗高增殖和/或血管生成性疾病，如癌症。这种治疗可以作为单药疗法或与其他药物或其他治疗措施联合使用。
• Unnatural Amino Acid-Substituted (Hydroxyethyl)urea Peptidomimetics Inhibit γ-Secretase and Promote the Neuronal Differentiation of Neuroblastoma Cells
  作者：Yung-Feng Liao、Bo-Jeng Wang、Wen-Ming Hsu、Hsinyu Lee、Chia-Yin Liao、Shin-Ying Wu、Hui-Ting Cheng、Ming-Kuan Hu

  DOI：10.1124/mol.106.024299

  日期：2007.2

  γ-Secretase, exhibiting characteristics of aspartyl protease, mediates the intramembranous proteolysis of β-amyloid precursor protein (APP) and Notch, and it is considered to be a prime pharmacological target in the development of therapeutics for Alzheimer's disease (AD). To identify compounds that block γ-secretase-mediated proteolysis, we used a highly sensitive cell-based reporter gene assay for γ-secretase in which Gal4/VP16-tagged C99-APP was expressed as the immediate substrate of γ-secretase, and Gal4/VP16-tagged APP intracellular domain released by the γ-secretase cleavage then activated the expression of the Gal4-driven luciferase reporter gene. Using this reporter assay, we demonstrated that the newly synthesized (hydroxyethyl)urea peptidomimetics, which contain unnatural amino acid moieties at positions P1′ and/or P3′, can effectively inhibit γ-secretase activity and significantly reduce Aβ production. The γ-secretase-dependent S3 cleavage of Notch was also consistently blocked by these (hydroxyethyl)ureas as evidenced by the decreased generation of the Notch intracellular domain, a prerequisite for the activation of Notch signaling. The inhibition of Notch signaling by active Jia compounds efficiently promotes the neuronal differentiation of neuroblastoma cells, intervening in tumorigenesis and the malignancy of neuroblastomas. Our results suggest that (hydroxyethyl)urea peptidomimetics containing unnatural amino acid substitutions could represent a novel class of γ-secretase inhibitors with enhanced stability, providing the basis for the further development of effective therapeutics for AD and neuroblastomas.

  γ-分泌酶作为一种天冬氨酸蛋白酶，介导β淀粉样蛋白前体蛋白(APP)和Notch的跨膜蛋白水解作用，被认为是阿尔茨海默病(AD)治疗药物开发的主要药理学靶点。为了鉴定阻断γ-分泌酶介导的蛋白水解作用的化合物，我们使用了一种高度灵敏的基于细胞的报告基因检测方法，其中表达Gal4/VP16标记的C99-APP作为γ-分泌酶的直接底物，经过γ-分泌酶切割释放的Gal4/VP16标记的APP胞内域激活Gal4驱动的荧光素酶报告基因的表达。利用这一报告检测方法，我们证明新合成的(羟乙基)脲类拟肽，在P1′和/或P3′位置含有非天然氨基酸基团，能有效抑制γ-分泌酶活性并显著减少Aβ产生。γ-分泌酶依赖的Notch S3切割也被这些(羟乙基)脲类持续阻断，通过减少Notch胞内域的生成来证实，这是Notch信号激活的前提。活性Jia化合物抑制Notch信号有效地促进神经母细胞瘤细胞的神经分化，干预神经母细胞瘤的形成和恶性。我们的结果表明，含有非天然氨基酸替代的(羟乙基)脲类拟肽可能代表一类新的具有增强稳定性的γ-分泌酶抑制剂，为进一步开发有效的AD和神经母细胞瘤治疗药物提供了基础。
• HIV protease inhibiting compounds
  申请人：Randolph T. John

  公开号：US20050159469A1

  公开（公告）日：2005-07-21

  A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

  公开了一种公式的化合物作为HIV蛋白酶抑制剂。还公开了用于抑制HIV感染的方法和组合物。